Emma Pristo

New study highlights telehealth struggles in cancer care

March 17, 2023 A 2023 study explored the significant stress cancer patients experienced during the COVID-19 pandemic, particularly due to restrictions that prevented informal caregivers or support persons from attending appointments and treatments. The research highlighted how these restrictions, combined with the shift to telehealth, led to increased social isolation and a loss of vital […]
Read more

Injection Immunotherapies Get FDA Approval

February 10, 2025 This article describes how Tecentriq Hybreza (atezolizumab and hyaluronidase) became the first injectable anti-PD-L1 immunotherapy approved by the FDA, followed by the December approval of Opdivo Qvantig (nivolumab and hyaluronidase) to treat a range of cancers including melanoma, lung, liver, and skin cancers. Clinical trials showed similar effectiveness between injection and infusion […]
Read more

Integrated Proteogenomic Characterization of Glioblastoma Evolution: Overcoming Barriers to Develop Personalized Treatment Strategies

March 19, 2025 This article highlights how one reason for limited progress in glioblastoma treatment in recent years is the lack of understanding of tumor behavior at the proteomic and spatial levels. Integrated proteogenomic characterization—combining genomics, transcriptomics, and proteomics—has emerged as a promising approach to identify patient-specific molecular signatures. These insights can be used to […]
Read more

Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy

April 24, 2025 Siren Biotechnology at UCSF is developing the first universal AAV-based gene therapy for solid tumors, starting with brain cancers like high-grade gliomas. To fund its upcoming first-in-human clinical trial, Siren launched a community investment round via Wefunder, seeking $50,000–$5 million. Its lead therapy, SRN-101, combines gene therapy with cytokine immunotherapy and has […]
Read more